Rekombinanter CD39 Antikörper

Produktnummer ABIN8093139

Der Maus Monoklonal anti-CD39 Antikörper (Klon r22A9) (ABIN8093139) detektiert spezifisch CD39 in IHC. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter CD39 Antikörper (ABIN8093139)

Target: CD39 (ENTPD1) (Ectonucleoside Triphosphate diphosphohydrolase 1 (ENTPD1))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD39 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Güteklasse: Carrier-free

Klon: R22A9

Produktdetails anti-CD39 Antikörper

Verwendungszweck: CD39 Antibody / ENTPD1 (azide and preservative free)

Immunogen: Prokaryotic recombinant protein corresponding to a portion of the external domain of the CD39 molecule was used as the immunogen for the ENTPD1/Ectonucleoside triphosphate diphosphohydrolase 1 antibody.

Isotyp: IgG2a, kappa

Anwendungsinformationen

Applikationshinweise: 1. Optimal dilution of the ENTPD1/Ectonucleoside triphosphate diphosphohydrolase 1 antibody should be determined by the researcher.

2. This ENTPD1/Ectonucleoside triphosphate diphosphohydrolase 1 antibody is recombinantly produced by expression in CHO cells.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: ENTPD1/Ectonucleoside triphosphate diphosphohydrolase 1 antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Details zu CD39

Target: CD39 (ENTPD1) (Ectonucleoside Triphosphate diphosphohydrolase 1 (ENTPD1))

Andere Bezeichnung: CD39

Hintergrund: ENTPD1 Antibody recognizes CD39, also known as Ectonucleoside triphosphate diphosphohydrolase 1, a plasma membrane ectoenzyme that regulates extracellular nucleotide signaling. Encoded by the ENTPD1 gene, CD39 hydrolyzes extracellular ATP and ADP to AMP, thereby modulating purinergic signaling pathways involved in inflammation, thrombosis, and immune regulation. ENTPD1 Antibody is suitable for detecting CD39 expression in research applications focused on immune homeostasis and tumor microenvironment biology.

ENTPD1 antibody, also referred to as CD39 antibody and NTPDase1 antibody in the literature, targets a glycosylated transmembrane protein expressed on endothelial cells, regulatory T cells, B cells, monocytes, macrophages, and selected epithelial populations. By limiting extracellular ATP and cooperating with CD73 to generate adenosine, CD39 contributes to immunosuppressive signaling pathways that regulate lymphocyte activation and maintain vascular homeostasis. Increased CD39 expression has been associated with immune tolerance and tumor-associated immune suppression.

The ENTPD1 gene is located on chromosome 10q24.1 and encodes a protein containing two transmembrane regions and a large extracellular catalytic domain with conserved apyrase motifs required for nucleotide hydrolysis. CD39 localizes predominantly to the plasma membrane and demonstrates membranous staining in endothelial and immune cell populations in tissue sections. Expression is particularly prominent in lymphoid tissues such as tonsil and lymph node, as well as in vascular endothelium and placenta.

Dysregulation of ENTPD1 expression has been implicated in cancer progression, chronic inflammatory disease, thrombosis, and cardiovascular disorders. Clone r22A9 is a recombinant mouse monoclonal antibody developed to recognize ENTPD1 / CD39 in experimental systems.

UniProt: P49961